MODICON 21 Drug Patent Profile
✉ Email this page to a colleague
When do Modicon 21 patents expire, and when can generic versions of Modicon 21 launch?
Modicon 21 is a drug marketed by Ortho Mcneil Pharm and is included in one NDA.
The generic ingredient in MODICON 21 is ethinyl estradiol; norethindrone. There are twenty-six drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norethindrone profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for MODICON 21?
- What are the global sales for MODICON 21?
- What is Average Wholesale Price for MODICON 21?
Summary for MODICON 21
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 7 |
Patent Applications: | 131 |
Formulation / Manufacturing: | see details |
DailyMed Link: | MODICON 21 at DailyMed |
US Patents and Regulatory Information for MODICON 21
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ortho Mcneil Pharm | MODICON 21 | ethinyl estradiol; norethindrone | TABLET;ORAL-21 | 017488-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |